Rocket Lab's Neutron Timeline Stretches to 2027 After Tank Manufacturing Flaw, Forcing Analysts to Rework Their Models

Rocket Lab investors absorbed a punishing session on Friday, with the stock shedding 8.2 percent to close at 45.25 euros. The trigger was a regulatory filing that pushed the maiden flight of the company's Neutron launch vehicle into 2027 — a full year beyond the fourth quarter of 2026 that management had previously held out as the target.

At the root of the slip is a manufacturing defect in the carbon-fibre composite structure of the first stage's fuel dome. A change in the production sequence introduced air pockets into the forward tank domes, according to the company's disclosure to the US Securities and Exchange Commission on Form 8-K, which came alongside a development-status presentation. Rocket Lab said it has already traced the cause and is implementing corrective measures in its manufacturing process. Reuters reported that the announcement served as the decisive catalyst for the immediate sell-off.

Two Houses, Two Cuts, One Message

Wall Street's response came in stages. KeyBanc trimmed its price target to $100 on Thursday, citing the revised schedule as well as valuation pressure across high-growth space names. Citizens followed on Friday, cutting its target from $130 to $90 while keeping its "Market Outperform" rating. The analysts tied the move directly to the delayed introduction of the Neutron launch system and the knock-on effects for future launch monetisation, according to media reports. Earlier, on 9 October, TD Cowen had already reduced its target from $120 to $90 in a third-quarter preview, leaving its "Buy" rating untouched.

The pattern across all three houses is consistent: none questions whether Neutron can be built, only when the revenue will arrive. The commercial case for the new medium-lift rocket remains intact, even if the earnings contribution now lands later than hoped.

A Week to Forget

The reassessment has left deep marks on the share price. Over seven days the stock has fallen 26 percent, and Friday's close leaves it 66 percent below its 52-week high of 133.80 euros. For holders, the pace of the Neutron programme has become the single dominant variable for the medium-term outlook.

Engineering Setbacks, Not Engineering Failure

Much of the market reaction reads as shock at a schedule reset rather than a verdict on the programme itself. Delays of this kind are routine when a company develops an entirely new launch vehicle from scratch, and catching flaws on the ground is precisely what quality control is for. Had Rocket Lab pressed ahead with a flawed test flight, an explosion could have set the programme back by years. Management has chosen the harder but more responsible path.

The timing is what stings. Investors had already priced in specific milestones, and they must now summon considerably more patience. Yet the underlying business keeps moving: while Neutron work is adjusted, the company is preparing the next launch of its established Electron rocket for the customer HawkEye 360.

For long-term shareholders, the current stretch is a test of nerve. The sell-off captures the shock of a shifted timeline, but it says little about the fundamental viability of a company with a working launch fleet and a demonstrated willingness to confront its manufacturing problems head-on. Those able to ride out the inevitable swings of the space sector may come to see this correction as a standard trial on a technically demanding path.